News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,984 Results
Type
Article (39733)
Company Profile (249)
Press Release (659002)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204242)
Career Advice (2007)
Deals (35431)
Drug Delivery (95)
Drug Development (81088)
Employer Resources (172)
FDA (16190)
Job Trends (14865)
News (345318)
Policy (32555)
Tag
Academia (2555)
Accelerated approval (5)
Adcomms (20)
Allergies (85)
Alliances (49472)
ALS (88)
Alzheimer's disease (1378)
Antibody-drug conjugate (ADC) (126)
Approvals (16194)
Artificial intelligence (252)
Autoimmune disease (21)
Automation (16)
Bankruptcy (361)
Best Places to Work (11645)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (176)
Bladder cancer (77)
Brain cancer (28)
Breast cancer (279)
Cancer (2258)
Cardiovascular disease (173)
Career advice (1676)
Career pathing (30)
CAR-T (150)
Cell therapy (421)
Cervical cancer (19)
Clinical research (66012)
Collaboration (836)
Compensation (530)
Complete response letters (19)
COVID-19 (2589)
CRISPR (40)
C-suite (240)
Cystic fibrosis (100)
Data (2196)
Decentralized trials (2)
Denatured (18)
Depression (42)
Diabetes (270)
Diagnostics (6368)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (121)
Drug pricing (98)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86605)
Editorial (37)
Employer branding (21)
Employer resources (146)
Events (112414)
Executive appointments (722)
FDA (17435)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (747)
Gene editing (104)
Generative AI (19)
Gene therapy (302)
GLP-1 (710)
Government (4418)
Grass and pollen (4)
Guidances (59)
Healthcare (18821)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (116)
Indications (29)
Infectious disease (2731)
Inflammatory bowel disease (137)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (311)
IPO (16513)
IRA (40)
Job creations (3631)
Job search strategy (1422)
Kidney cancer (10)
Labor market (38)
Layoffs (467)
Leadership (17)
Legal (7910)
Liver cancer (75)
Lung cancer (320)
Lymphoma (153)
Machine learning (7)
Management (58)
Manufacturing (305)
MASH (66)
Medical device (13378)
Medtech (13383)
Mergers & acquisitions (19461)
Metabolic disorders (683)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (88)
Neuropsychiatric disorders (27)
Neuroscience (1911)
NextGen: Class of 2025 (6521)
Non-profit (4480)
Now hiring (39)
Obesity (363)
Opinion (205)
Ovarian cancer (76)
Pain (85)
Pancreatic cancer (83)
Parkinson's disease (148)
Partnered (21)
Patents (233)
Patient recruitment (110)
Peanut (46)
People (57312)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20567)
Phase II (29067)
Phase III (21659)
Pipeline (1184)
Policy (138)
Postmarket research (2563)
Preclinical (8743)
Press Release (64)
Prostate cancer (108)
Psychedelics (30)
Radiopharmaceuticals (269)
Rare diseases (378)
Real estate (5909)
Recruiting (65)
Regulatory (22288)
Reports (46)
Research institute (2320)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (68)
Series A (129)
Series B (84)
Service/supplier (11)
Sickle cell disease (52)
Special edition (15)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3581)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (39)
The Weekly (31)
Vaccines (686)
Venture capitalists (41)
Weight loss (235)
Women's health (35)
Worklife (16)
Date
Today (173)
Last 7 days (871)
Last 30 days (2631)
Last 365 days (32862)
2025 (10615)
2024 (35262)
2023 (40112)
2022 (51195)
2021 (55726)
2020 (54095)
2019 (46558)
2018 (35027)
2017 (32115)
2016 (31491)
2015 (37561)
2014 (31334)
2013 (26350)
2012 (28577)
2011 (29276)
2010 (27337)
Location
Africa (719)
Alabama (53)
Alaska (7)
Arizona (231)
Arkansas (13)
Asia (37856)
Australia (6199)
California (6102)
Canada (2010)
China (521)
Colorado (265)
Connecticut (272)
Delaware (146)
Europe (81337)
Florida (907)
Georgia (205)
Idaho (57)
Illinois (534)
India (25)
Indiana (307)
Iowa (11)
Japan (162)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (887)
Massachusetts (4564)
Michigan (219)
Minnesota (390)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1720)
New Mexico (28)
New York (1737)
North Carolina (964)
North Dakota (8)
Northern California (2666)
Ohio (203)
Oklahoma (14)
Oregon (34)
Pennsylvania (1372)
Puerto Rico (12)
Rhode Island (33)
South America (1098)
South Carolina (22)
South Dakota (1)
Southern California (2289)
Tennessee (101)
Texas (905)
United States (23038)
Utah (181)
Virginia (144)
Washington D.C. (61)
Washington State (550)
West Virginia (3)
Wisconsin (54)
698,984 Results for "avid radiopharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Radiopharmaceuticals
5 Big Pharmas Push Boundaries in Radiopharmaceuticals
While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their radiopharmaceutical assets to a market projected to be worth over $13 billion by 2033.
March 31, 2025
·
9 min read
·
Tristan Manalac
Press Releases
Avidity Biosciences to Participate in Upcoming Investor Conferences
February 25, 2025
·
2 min read
Biotech Beach
Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock - June 14, 2024
Avidity Biosciences, Inc. announced the pricing of an underwritten public offering of 10,550,000 shares of its common stock at a price to the public of $38.00 per share.
June 13, 2024
·
5 min read
Press Releases
Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger
February 6, 2025
·
6 min read
Biotech Beach
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock - June 12, 2024
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that it intends to offer and sell, subject to market and other conditions, $300.0 million of shares of its common stock in an underwritten public offering.
June 12, 2024
·
5 min read
Biotech Beach
Avidity Biosciences to Participate in Upcoming June 2024 Investor Conference
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Avidity management will be participating at the following upcoming conference.
June 14, 2024
·
1 min read
Press Releases
Avid Stockholders Approve Transaction with GHO and Ampersand
January 31, 2025
·
4 min read
Press Releases
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
April 8, 2025
·
9 min read
Press Releases
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
March 13, 2025
·
4 min read
Press Releases
Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights
February 27, 2025
·
13 min read
1 of 69,899
Next
